Identification and validation of AKR1C1/2/3 as hepatocellular carcinoma risk modules via an integrated strategy

CURRENT STATUS: POSTED

Mingxing Xu
Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Yuesi Zhong
Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Fangji Yang
Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Kai Liu
Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Baoding Zhuang
Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Ruiyun Xu
Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Yunbiao Ling
Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Nan Lin
Sun Yat-Sen University

Corresponding Author
DrLinNan6@163.com
ORCiD: https://orcid.org/0000-0002-4635-3966
Abstract

Background

The human aldo-keto reductase 1 (AKR1) C family comprises four enzymes, AKR1C1-AKR1C4. Lots of studies have investigated the function of AKR1Cs in tumors, however little is known in hepatocellular carcinoma (HCC).

Methods

Public databases were used to explore expression and role of AKR1Cs in HCC. Meanwhile, data of 134 HCC patients from Firebrowse website was used for validation.

Results

The results revealed that AKR1Cs expression was negatively correlated with the infiltration level of CD4+ T cells. Overexpression of AKR1C1/2/3 was significantly associated with tumor stage and pathological grade. Moreover, higher mRNA expression of AKR1C1/2/3 was related with shorter overall survival (OS), progression-free survival (PFS) and relapse-free survival (RFS). Multivariate Cox regression analysis showed that AKR1C1/2/3 could be significant risk factors for HCC patients. Additionally, genetic alterations of AKR1Cs can significantly affect patient OS and PFS, and expression of AKR1Cs was linked to functional networks involving oxidation-reduction process, cellular hormone metabolic process and organic hydroxy compound metabolic process, as well as retinol metabolism, steroid hormone biosynthesis, metabolic pathway and fatty acid degradation pathways.

Conclusions

In conclusion, we successfully elaborated the relationship between AKR1Cs expression and immune infiltrations, and identified AKR1C1/2/3 could be novel prognostic biomarkers for HCC patients.

Background

Hepatocellular carcinoma (HCC) is the 6th common tumor and the most frequent primary liver cancer. Due to its poor prognosis, HCC has always been a topic of great concern [1]. Although research is endless, exact mechanism of HCC occurrence and metastasis remains unclear, exploring and discovering new prognostic biomarkers are needed and can provide theoretical basis for conquering this disease in the future.
AKR1C family, consisting of AKR1C1-AKR1C4, is a critical subgroup of AKR family. AKR1Cs mainly focus on catalyzing NADPH dependent reductions and have been involved in apoptosis, intermediary metabolism, and malignant transformation [2]. Mounting evidence has revealed roles of AKR1C family members in a variety of solid tumors [3–6], especially in cancer occurrence, progression and anticancer treatment [7]. No enough evidence about comprehensive roles of the AKR1C family can be found in HCC. Hence, systematic inquiry of AKR1Cs is needed and has great benefits to reveal the mechanisms in HCC development.

In this study, we systematically explored the expression and function of AKR1C family members in HCC using bioinformatics data mining. We identified the expression levels of AKR1C1/2/3 were differentially overexpressed in cancerous tissues comparing to normal tissues. Moreover, AKR1C1/2/3 can jointly predict the prognosis in HCC patients, and low expressions were favorable. Besides, genetic alteration of AKR1Cs and the neighboring genes were analyzed in HCC to reveal that these genes could affect the occurrence and development of tumors through common carcinogenic pathways.

Methods

CCLE

Different tumor cell line expression profiling assays were downloaded from CCLE database (https://portals.broad institute.org/ccle/home), usage of this database can facilitate the identification of genetic, lineage and predictors of drug sensitivity [8].

ONCOMINE

ONCOMINE database (www.oncomine.org) is the most commonly used database for carcinogenic gene mining [9]. The mRNA levels of distinct AKR1C members between different cancer tissues and corresponding adjacent normal samples were determined through this platform. The filter conditions were set as follows: the fold change was defined as 1.5 and p < 0.01 were considered significant.

UALCAN

UALCAN is an online analysis tool for public data, whose resource mainly comes from level 3 RNA-seq and clinical data of 31 cancer types from The Cancer Genome Atlas (TCGA) database [10]. In present
study, mRNA expression of AKR1C members and their association with clinicopathologic parameters were analyzed using this tool, UALCAN can be publicly available at http://ualcan.path.uab.edu.

Timer

The Timer database (https://cistrome.shinyapps.io/timer/) is a tool which can be used for analysis between gene expression and immune infiltration across different cancer types [11]. Herein, expression of four AKR1C members was analyzed in HCC patients, and the immune infiltrates consisted of B cell, CD8+ T cell, CD4+ T cell, macrophage, neutrophil and dendritic cell.

GEPIA

GEPIA (http://gepia.cancer-pku.cn/) is an online integration web tool developed by Peking University, it concludes RNA-seq data of 9,736 tumor samples and 8,587 normal samples from TCGA and GTEX [12]. In this study, we analyzed the associations of AKR1C members and gene markers of T cell exhaustion using this server.

STRING

The protein-protein interaction (PPI) network was constructed using STRING online database (https://string-db.org/) [13]. The association of AKR1C members was calculated and score values for evaluating the extent of relevance could be obtained.

Kaplan-meier Plotter

Kaplan-Meier plotter (http://kmplot.com/analysis/) is a widely used online survival analysis tool. In this study, prognostic values of AKR1C members in HCC samples were evaluated by analyzing OS, RFS, PFS and disease-specific survival (DSS).

cBioPortal and g:Profiler

The cBio Cancer Genomics Portal (http://cbioportal.org) is mainly used for exploration of multidimensional cancer genomics data sets [14]. In this study, genetic mutations of AKR1Cs and impacts on OS and DFS in HCC patients were analyzed. Neighboring genes were subsequently used to perform gene ontology (GO) and KEGG analyses by g:Profiler (http://biit.cs.ut.ee/gprofiler/) [15]. GO annotation has three parts: cellular component (CC), biological process (BP) and molecular function (MF).
Linkedomics

The LinkedOmics database (http://www.linkedomics.org/login.php) [16] was used to analyze the correlation between differentially expressed genes and AKR1C members in the TCGA HCC cohort (n = 371), and to assess the correlation of genes by Pearson’s coefficient. Similarly, the Web-based Gene SeT AnaLysis Toolkit (WebGestalt) [17] was then used to perform GO and KEGG analyses of these related genes.

Statistical Analyses

Univariate and multivariate analyses were performed using Cox proportional hazards model. All analyses were performed using SPSS version 22.0 (IBM, United States). A 2-tailed p value < 0.05 was considered statistically significant.

Results

Expression profiles of AKR1Cs in HCC

To investigate values of AKR1Cs in HCC patients, we first analyzed expression of AKR1Cs by CCLE, ONCOMINE and UALCAN databases. CCLE analysis demonstrated that mRNA expression of four members in HCC cell lines all ranked forefront levels among the common cancer cell lines, moreover AKR1C1 and AKR1C4 ranked the top level (Fig. 1a). Analysis by ONCOMINE database showed that AKR1C3 mRNA level was significantly higher in cancerous tissue than in normal samples, however AKR1C4 mRNA expression was lower in HCC tissues (Additional file 1: Figure S1a). Meta-analysis of multiple datasets indicated significantly higher levels of AKR1C1/2/3 in HCC than in normal tissues (Additional file 1: Figure S1b). In Roessler Liver 2 dataset [18], AKR1C3 over-expression was found in HCC tissues compared with normal tissues with a fold change of 3.438 (p = 3.86E-71) (Additional file 2: Figure S2a), Wurmbach Liver dataset [19] also showed AKR1C3 was over-expressed in HCC (Additional file 2: Figure S2b). AKR1C2 was over-expressed with a fold change of 1.543 (p = 4.53E-4) in Wurmbach Liver dataset (Additional file 2: Figure S2c).

To further explore mRNA expression levels of AKR1Cs in HCC, we used UALCAN database, whose data resource was totally different from ONCOMINE, to conduct this analysis. As shown in Fig. 1b, mRNA expressions of AKR1C1/2/3 were proved to be significantly higher in tumor tissues than in normal
samples (all $p < 0.05$).

**Correlation of AKR1Cs mRNA level with clinical indicators in HCC patients**

Combined with above results, we concluded that AKR1C1/2/3 was significantly high-expressed in HCC tissues. Then we investigated the relationship between respective expression level and clinical indicators in HCC patients. Sub-group analysis of multiple clinic pathological features of HCC samples in UALCAN database consistently showed higher transcription level of AKR1C1/2/3 in HCC patients than in healthy human based on gender, age and tumor stage (Fig. 1c, d, e). Further analyzing the results of mRNA expression with tumor grade, we found that transcription levels of AKR1C1/2/3 were apparently correlated with tumor grade in HCC patients, patients with higher tumor grade tend to have higher expression of AKR1C1/2/3 (Fig. 1f).

**Relationship of expression of AKR1Cs and immune infiltration and T cell exhaustion in HCC**

The correlation between AKR1Cs expression and immune invasion in HCC was evaluated using Timer database in this study. The results showed that the infiltration levels of CD4$^+$ T cells were negatively correlated with the expression of all AKR1C members (Fig. 2, all $p < 0.05$), and levels of infiltrated macrophages were also negatively correlated with AKR1C1/2/4 expression (Fig. 2).

Next, we used the GEPIA database to identify the relationship between AKR1Cs expression and T cell exhaustion markers including PD-1, LAG3, GZMB and CTLA4 in tumor and normal tissues. Our results showed that there was a negative correlation of AKR1C2/4 and PD-1 in tumor tissues ($p < 0.05$, Additional file 3: Table S1), but no significant correlations between remaining members and other markers.

**Elevated AKR1C1/2/3 Expression Predicted Poor Prognosis In HCC Patients**

To analyze the prognosis values of distinct AKR1C members in HCC patients, Kaplan-Meier plotter was used and the results showed that patients with high mRNA level of AKR1C1 (hazard ratio (HR) = 1.78, 95% confidence interval (CI): 1.25–2.52, and $p = 0.0012$), AKR1C2 (HR = 1.51, 95% CI: 1.04–2.18, and $p = 0.028$) and AKR1C3 (HR = 1.69, 95% CI: 1.2–2.4, and $p = 0.0027$) had poor OS (Fig. 3a). However high mRNA expression of AKR1C4 (HR = 0.68, 95% CI: 0.47–0.97, and $p = 0.035$) was associated with favorable OS (Fig. 3a). Integration analysis of multiple members showed that high combinatory mRNA
expression of AKR1C1/2/3 (HR = 1.88, 95% CI: 1.32–2.67, and p = 4E-04) or all members (HR = 1.86, 95% CI: 1.3–2.65, and p = 0.00053) was significantly associated with poor OS in HCC patients (Fig. 3a). Similar results were observed when analyzing PFS, RFS and DSS (Fig. 3b, c, d). Taken together, these results indicated that high mRNA expression of AKR1C1/2/3 was significantly correlated with poor prognosis in HCC patients and AKR1C1/2/3 could be viewed as significant risk indicators.

Validation Of AKR1C1/2/3 Expression On OS In HCC Patients

Data of clinical indicators and mRNA expression of AKR1Cs in HCC patients was downloaded from the TCGA database through the Firebrowse website (http://firebrowse.org/api-docs/) when conducting Cox survival regression analyses. After screening by professional assessment and data integrity, we included 134 patients with complete data and 16 clinical indicators in this study (Table 1). The results of univariate and multivariate analyses were summarized in Table 2. In univariate analysis, total bilirubin (TB) (HR = 42.737, 95% CI: 9.568-190.886, and p < 0.001) and surgical margin (HR = 4.935, 95% CI: 1.920-12.685, and p = 0.001) were identified as independent risk factors of patient OS. Multivariate analysis revealed that albumin (HR = 1.350, 95% CI: 1.064–1.714, and p = 0.013), prothrombin time (PT) (HR = 1.140, 95% CI: 1.047–1.241, and p = 0.002), TB (HR = 5859.486, 95% CI: 407.319-84291.531, and p < 0.001), tumor necrosis (HR = 1.054, 95% CI: 1.002–1.109, and p = 0.043), surgical margin (HR = 12.774, 95% CI: 3.692–44.196, and p < 0.001) together with mRNA levels of AKR1C1/2/3 (all p < 0.05) were significantly associated with patient OS.

Genomic alterations and biological interaction network of AKR1Cs in HCC

Next, we used cBioPortal, which was based on sequencing data from the TCGA database to explore genetic alterations of AKR1Cs and their associations with prognostic indicators in HCC patients. As shown in Fig. 4a, AKR1Cs were altered in 70 of 370 (19%) patients and AKR1C2 ranked the highest level (the mutation rate was 11%). Among these alterations, 54 patients had mRNA upregulation (14.59%), 7 cases had amplification (1.89%) and only 2 cases had deep deletion (0.54%) (Additional file 4: Table S2). To further investigate the roles of genomic alterations of AKR1Cs in HCC, we conducted survival analysis and the results showed that patients with AKR1Cs alterations had poor OS
and PFS (Fig. 4b, c, all p < 0.05), indicating that genomic alterations of AKR1Cs had significant impacts on patient prognosis in HCC.

Table 1
Clinicopathological variables of 134 HCC specimens with complete data

| variables | HCC patients (N = 134) |
|-----------|-------------------------|
| Gender (Male/female) | 91/43 |
| Age (years, Mean ± SD) | 58.65 ± 13.42 |
| Weight (kg, Mean ± SD) | 71.29 ± 16.30 |
| Adjacent tissue inflammation | |
| none | N = 58 |
| mild | N = 62 |
| severe | N = 14 |
| Albumin (g/L, Median) | 3.95 (0.20–5.10) |
| Childpugh stage | |
| A | N = 122 |
| B | N = 12 |
| AFP (ng/ml, Median) | 9 (1–2035000) |
| Platelet (10^9/L, Median) | 198.5 (69–334000) |
| PT (s, Median) | 1.1 (0.8–19) |
| TB (µmol/L, Median) | 1.2 (1–1.5) |
| Fibrotic score | |
| no fibrosis | N = 42 |
| portal fibrosis | N = 18 |
| fibrous speta | N = 19 |
| nodular formation and incomplete cirrhosis | N = 5 |
| established cirrhosis | N = 50 |
| Histologic grade | |
| g1 | N = 13 |
| g2 | N = 68 |
| g3 | N = 48 |
| g4 | N = 5 |
| Vascular invasion (yes/no) | 40/94 |
| Tumor weight (g, Median) | 150 (50–1400) |
| Tumor necrosis (%Median) | 5 (0–30) |
| Surgical margin (positive/negative) | 6/128 |

HCC hepatocellular carcinoma, AFP alpha-fetoprotein, PT prothrombin time, TB total bilirubin, SD standard deviation
Table 2
Prognostic factors associated with OS in 134 HCC specimens with complete data

| Variables                        | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR                  | 95% CI                | P value | HR | 95% CI | P value |
| Gender                           |                     |                       |         |    |        |         |
| Age (years)                      |                     |                       |         |    |        |         |
| Weight (kg)                      |                     |                       |         |    |        |         |
| Adjacent tissue inflammation     |                     |                       |         |    |        |         |
| Albumin (g/L)                    | 1.350               | 1.064–1.714           | 0.013*  |    |        |         |
| Childpugh stage                  |                     |                       |         |    |        |         |
| AFP (ng/ml)                      |                     |                       |         |    |        |         |
| Platelet (10^9/L)                | 1.140               | 1.047–1.241           | 0.002*  |    |        |         |
| PT (s)                           | 42.737              | 9.568–190.886         | 0.000*  | 5859.486 | 407.319–84291.531 | 0.000* |
| TB (µmol/L)                      |                     |                       |         |    |        |         |
| Fibrotic score                   |                     |                       |         |    |        |         |
| Histologic grade                 |                     |                       |         |    |        |         |
| Vascular invasion                |                     |                       |         |    |        |         |
| Tumor weight                     |                     |                       |         |    |        |         |
| Tumor necrosis (%)               | 1.054               | 1.002–1.109           | 0.043*  |    |        |         |
| Surgical margin                  | 4.935               | 1.920–12.685          | 0.001*  | 12.774 | 3.692–44.196 | 0.000* |
| AKR1C1                           | 1.000               | 1.000–1.000           | 0.023*  |    |        |         |
| AKR1C2                           | 1.000               | 1.000–1.000           | 0.001*  |    |        |         |
| AKR1C3                           | 1.000               | 1.000–1.000           | 0.029*  |    |        |         |
| AKR1C4                           | 1.000               | 1.000–1.000           | 0.029*  |    |        |         |

Variables with p < 0.05 were marked with asterisk (*)

OS over survival, HCC hepatocellular carcinoma, AFP alpha-fetoprotein, PT prothrombin time, TB total bilirubin

We then planned to study the biological interaction network of AKR1Cs in HCC using the Network tool in cBioPortal, and Fig. 4d showed the constructed network of neighboring genes associating with AKR1Cs mutations. The most frequent alterations were RDH10 (21.1%) and ADH5 (6.8%) among these neighboring genes (Additional file 5: Table S3). Functions of AKR1Cs and the frequently altered neighboring genes were enriched by g:Profiler website (Additional file 6: Table S4). Results of enriched GO terms indicated that these genes encode proteins localized mainly in endoplasmic reticulum membrane, nuclear outer membrane and endoplasmic reticulum part (Fig. 4e). These proteins are primarily involved in oxidation-reduction process, cellular hormone metabolic process and organic hydroxy compound metabolic process (Fig. 4f), while they were also associated with oxidoreductase activity and steroid dehydrogenase activity (Fig. 4g). In KEGG analysis, it was suggested that retinol metabolism, steroid hormone biosynthesis, metabolic pathway and fatty acid degradation pathway (Fig. 4h) all showed enrichments, which indicated the possible pathways of
AKR1Cs mutation in HCC.

Construction of PPI network and enrichment analysis of AKR1Cs functional networks in HCC

PPI network was constructed using STRING database, and the results indicated that there was a close positive correlation between any two of AKR1C1/2/3 members. However, AKR1C4 is much less relevant with remaining members (Fig. 4i-l and Additional file 7: Table S5).

The LinkedOmics database, containing mRNA sequencing data of 371 HCC patients in the TCGA was used to analyze co-expression genes correlated with AKR1Cs in HCC. As shown in Fig. 5a, volcano plot indicated genes with significant positive and negative correlations with AKR1C1 (false discovery rate [FDR] < 0.01). And the top 3 positively correlated genes with AKR1C1 were showed in Additional file 8: Table S6, they were AKR1C2 (positive rank #1, Pearson correlation = 0.88, p = 1.16e–119), AKR1C3 (Pearson correlation = 0.66, p = 4.43e–48) and ALDH1L1 (Pearson correlation = 0.66, p = 5.45e–48).

The heat map showed the 50 significant gene sets positively and negatively correlated with AKR1C1 (Fig. 5a). The same method is used to analyze AKR1C2/3/4, and the results were shown in Fig. 5b, c, d, Additional file 8: Table S6 and Additional file 9: Table S7. All these results reflected that AKR1C1/2/3 had a strong positive correlation with each other, indicating the 3 members may play a synergistic role in function regulation. We then used gene set enrichment analysis (GSEA) to perform GO term and KEGG analyses and found that significant genes differentially expressed in correlation with AKR1C1 were located mainly in the mitochondria, ribosome and respiratory chain, while they were mainly involved in coenzyme metabolic process, cellular amino acid metabolic process and fatty acid metabolic process. At the same time, they play important roles in the structural constituent of ribosome, oxidoreductase activity and electron transfer activity (Fig. 6a). KEGG pathway analysis showed they were mainly enriched in ribosome, oxidative phosphorylation and carbon metabolism pathways (Fig. 6a). Similarly, we did similar analysis for AKR1C2/3/4, and results were shown in Fig. 6b, c, d and Additional file 10: Table S8.

Discussion

In HCC, roles of AKR1Cs alteration still remain largely unclear although a small number of studies indicated some members play an important role in the progression of liver cancer [20, 21].
Considered the deficiency of related researches, this study focuses on the expression levels, immune infiltrations, mutation status and prognostic values of different AKR1C members in HCC patients. Our results indicated that AKR1C1/2/3 members were distinctively high-expressed in HCC comparing to normal controls, and correlation analysis showed that there was a good positive correlation among the three members, which implied that there was a potential synergistic effect among the 3 members in HCC. And this was consistent with previous results of studies [6, 22]. Besides, AKR1C1/2/3 jointly acting as significant risk factors on prognosis was also validated in HCC patients.

High expression of AKR1C1 was observed in many solid tumors and increasing studies have used AKR1C1 as a therapeutic target for treatment of cancers [3, 23]. Our study firstly showed that AKR1C1 was also high-expressed in HCC tissues and high mRNA expression of AKR1C1 predicted poor OS and PFS. All the results indicated that AKR1C1 actively participated in the occurrence of tumors and can be regarded as a new target in future treatment of HCC. Meanwhile, our study also showed high mRNA expression of AKR1C2 predicted poor survival in HCC patients, which was in line with previous studies [20, 21]. However in breast cancer (BC), AKR1C2 expression in tumor cells suggested a positive correlation with DFS and OS, this opposite conclusion may be attributed to the characteristics of breast cancer itself [24]. Additionally, significant up-regulation of AKR1C3 was observed in acute lymphoblastic leukemia [25] and prostate cancer, promoting the development of prostate cancer and reduce the effect of chemotherapy [26]. These features were in line with the effect of AKR1C3 in current study, namely AKR1C3 positively correlated with tumor grade, and can be viewed as a new biological indicator for prognosis of HCC patients. Finally, AKR1C4 seems to play a conflicting role comparing with other members, moreover AKR1C4 and AKR1C3 seem to function mutually exclusive. This is consistent with our results that the coefficient of person-correlation is only 0.469, which is much lower than that with any other members (Additional file 8: Table S6 and Additional file 9: Table S7), indicating the least relevance between AKR1C4 and AKR1C3. Perhaps because of its uniqueness, the mRNA expression of AKR1C4 in HCC is lower than normal controls, and patient prognosis with high expression of AKR1C4 is exclusively favorable in HCC.

Tumor immune cell infiltration refers to the migration of immune cells from blood to surrounding
tissue. The infiltration of immune cells in tumors is closely related to patient clinical outcomes. Tumor infiltrating lymphocytes are independent predictors for patient survival in many cancers [27, 28]. As a key point of the anticancer effects, however, it remains much challenging to confirm the relationship of immune cell infiltrates with tumor cells and body immune system. A large number of studies elucidating inner mechanisms are needed for improving patient prognosis in cancer treatments. In the present study, although we have initially obtained the relationship between AKR1Cs expression and immune cells & some immune markers, it remains a lot to be explored which AKR1C member can specifically affect liver cancer growth through which immune cell.

Our research has many shortcomings although we systematically revealed for the first time the roles of AKR1C family members in HCC. First, most of the conclusions are mined from online public databases, a larger number of clinical samples and experimental studies are still needed to confirm the roles of these members in HCC. Second, the internal mechanism of AKR1Cs’ role in HCC and how different members of the family related to each other still need to be explored in the future.

Conclusions
Collectively, these bioinformatic and statistical findings provided multilevel evidence for the importance of AKR1C family members in hepatocarcinogenesis and its potential as a marker in HCC. Future work will focus on utilizing clinical parameters along with the biomarker to improve its performance in HCC.

Abbreviations
AKR1: aldo-keto reductase 1; HCC: hepatocellular carcinoma; OS: overall survival; PFS: progression-free survival; RFS: relapse-free survival; TCGA: The Cancer Genome Atlas; DSS: disease-specific survival; GO: gene ontology; CC: cellular component; BP: biological process; MF: molecular function; HR: hazard ratio; CI: confidence interval; TB: total bilirubin; PT: prothrombin time; AFP: alpha-fetoprotein; SD: standard deviation; FDR: false discovery rate; GSEA: gene set enrichment analysis.

Declarations
Acknowledgements
The authors gratefully acknowledge the public databases for their roles in the generation of data used in this study.
Author contributions
M.X.X., Y.S.Z. and F.J.Y. performed literature review, and compiled the data. M.X.X. wrote the
manuscript, and Y.S.Z. and F.J.Y. help in writing and reading and editing. K.L. and B.D.Z. help in the
literature review as well as assisted in preparing tables. Y.B.L., R.Y.X. and N.L. contributed to
designing and revising the manuscript. All authors read and approved the final manuscript.

Funding
This study was supported by the National Natural Science Fund of China (81470860), the National
Natural Science Foundation Regional Science Fund of China (81760112), the Science and Technology
Planning Project of Guangdong Province (2017b020247057) and the Science and Technology Planning
Project of Guangzhou (201804010211).

Availability of data and materials
Data and materials related to this work are available upon request.

Ethics approval and consent to participate
This study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen
University. Patient informed consent was obtained when the data were uploaded to a public database.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1Department of Hepatobiliary Surgery, The Third Affiliated Hospital of Sun Yat-sen University,
Guangzhou, Guangdong, China
2Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University,
Guangzhou, Guangdong, China

References
1. Forner A, Reig M, Bruix J: Hepatocellular carcinoma. Lancet 2018, 391:1301-1314.
2. Zeng CM, Chang LL, Ying MD, Cao J, He QJ, Zhu H, Yang B: Aldo-Keto Reductase
AKR1C1-AKR1C4: Functions, Regulation, and Intervention for Anti-cancer Therapy. 

*Front Pharmacol* 2017, 8:119.

3. Huebbers CU, Verhees F, Poluschkin L, Olthof NC, Kolligs J, Siefer OG, Henfling M, Ramaekers FCS, Preuss SF, Beutner D, et al: Upregulation of AKR1C1 and AKR1C3 expression in OPSCC with integrated HPV16 and HPV-negative tumors is an indicator of poor prognosis. *Int J Cancer* 2019, 144:2465-2477.

4. Johansson AG, Nikamo P, Schalling M, Landen M: Polymorphisms in AKR1C4 and HSD3B2 and differences in serum DHEAS and progesterone are associated with paranoid ideation during mania or hypomania in bipolar disorder. *Eur Neuropsychopharmacol* 2012, 22:632-640.

5. Lewis MJ, Wiebe JP, Heathcote JG: Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. *BMC Cancer* 2004, 4:27.

6. Li W, Hou G, Zhou D, Lou X, Xu Y, Liu S, Zhao X: The roles of AKR1C1 and AKR1C2 in ethyl-3,4-dihydroxybenzoate induced esophageal squamous cell carcinoma cell death. *Oncotarget* 2016, 7:21542-21555.

7. Ozgencli I, Budak H, Ciftci M, Anar M: Lichen Acids May Be Used as A Potential Drug For Cancer Therapy; by Inhibiting Mitochondrial Thioredoxin Reductase Purified From Rat Lung. *Anticancer Agents Med Chem* 2018, 18:1599-1605.

8. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature* 2012, 483:603-607.

9. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.
10. Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, Varambally S: UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. *Neoplasia* 2017, 19:649-658.

11. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS: TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. *Cancer Res* 2017, 77:e108-e110.

12. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z: GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. *Nucleic Acids Res* 2017, 45:W98-w102.

13. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, et al: STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019, 47:D607-d613.

14. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2012, 2:401-404.

15. Reimand J, Arak T, Vilo J: g:Profiler--a web server for functional interpretation of gene lists (2011 update). *Nucleic Acids Res* 2011, 39:W307-315.

16. Vasaikar SV, Straub P, Wang J, Zhang B: LinkedOmics: analyzing multi-omics data within and across 32 cancer types. *Nucleic Acids Res* 2018, 46:D956-d963.

17. Wang J, Vasaikar S, Shi Z, Greer M, Zhang B: WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. *Nucleic Acids Res* 2017, 45:W130-w137.

18. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang
ZY, Qin LX, Wang XW: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010, 70:10202-10212.

19. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, Thung S, Mazzaferro V, Bruix J, et al: Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45:938-947.

20. Li C, Wu X, Zhang W, Li J, Liu H, Hao M, Wang J, Zhang H, Yang G, Hao M, et al: AEG-1 Promotes Metastasis Through Downstream AKR1C2 and NF1 in Liver Cancer. Oncol Res 2014, 22:203-211.

21. Li C, Wu X, Zhang W, Li J, Liu H, Hao M, Wang J, Zhang H, Yang G, Hao M, et al: High-Content Functional Screening of AEG-1 and AKR1C2 for the Promotion of Metastasis in Liver Cancer. J Biomol Screen 2016, 21:101-107.

22. Hevir N, Vouk K, Sinkovec J, Ribic-Pucelj M, Rizner TL: Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis. Chem Biol Interact 2011, 191:217-226.

23. Zhu H, Chang LL, Yan FJ, Hu Y, Zeng CM, Zhou TY, Yuan T, Ying MD, Cao J, He QJ, Yang B: AKR1C1 Activates STAT3 to Promote the Metastasis of Non-Small Cell Lung Cancer. Theranostics 2018, 8:676-692.

24. Wenners A, Hartmann F, Jochens A, Roemer AM, Alkatout I, Klapper W, van Mackelenbergh M, Mundhenke C, Jonat W, Bauer M: Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. Int J Clin Oncol 2016, 21:548-556.

25. Moradi Manesh D, El-Hoss J, Evans K, Richmond J, Toscan CE, Bracken LS, Hedrick A, Sutton R, Marshall GM, Wilson WR, et al: AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia. Blood 2015,
126:1193-1202.

26. Verma K, Gupta N, Zang T, Wangtrakuldee P, Srivastava SK, Penning TM: AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells. 2018, 17:1833-1845.

27. Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF: Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 2012, 30:2678-2683.

28. Ohtani H: Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007, 7:4.

Additional Files

Additional file 1: Figure S1. Transcriptional expression of AKR1Cs in common types of cancers.

Additional file 2: Figure S2. AKR1C2/3 transcriptions in hepatocellular carcinoma.

Additional file 3: Table S1. Correlation between AKR1Cs and T cell exhaustion markers in tissues.

Additional file 4: Table S2. Genetic alterations of AKR1Cs in cBioPortal.

Additional file 5: Table S3. Neighboring genes associating with AKR1Cs mutations.

Additional file 6: Table S4. Enrichments of AKR1Cs and the frequently altered neighboring genes.

Additional file 7: Table S5. Correlation between any two of all AKR1C members.

Additional file 8: Table S6. Top 3 positively correlated genes of AKR1Cs.

Additional file 9: Table S7. Gene sets positively and negatively correlated with AKR1C4.

Additional file 10: Table S8. GO term and KEGG analyses of AKR1C2/3/4 by GSEA.

Figures
Expression profiles of AKR1Cs in HCC. (a) mRNA expression levels of AKR1C1, AKR1C2, AKR1C3 and AKR1C4 were analyzed using CCLE database. AKR1C1/4 ranked top levels among different cancer cell lines (emphasized in red frame). AKR1Cs transcription in subgroups of HCC patients, stratified based on tissue samples (b), gender (c), age (d), tumor stage (e) and tumor grade (f). *p < 0.05, **p < 0.01, ***p < 0.001
Figure 2

Associations between AKR1Cs and immune infiltration in HCC. The relationship of AKR1Cs [AKR1C1 (a), AKR1C2 (b), AKR1C3 (c) and AKR1C4 (d)] expression and immune infiltrations. AKR1C1/2/3/4 was negatively related with CD4+ T cell (emphasized in green frame), and AKR1C1/2/4 was negatively related with macrophage (emphasized in blue frame).
Figure 3

Prognostic values of AKR1Cs in HCC. Individual or joint analyses of AKR1Cs on OS (a), PFS (b), RFS (c) and DSS (d) in HCC patients
Genetic mutations, impacts on prognosis and interactions of AKR1Cs in HCC patients. (a)
Oncoprint of AKR1Cs alterations in HCC. The overview of genomic alterations showed that
mutation rate of AKR1Cs was 19%. And mutation rates of AKR1C2, AKR1C3, AKR1C1 and AKR1C4 were 11%, 10%, 9% and 8% respectively. Alterations of AKR1Cs poorly affect patient OS (b) and PFS (c) in HCC patients. (d) Network view of AKR1Cs and their altered neighboring genes in HCC. GO analysis [including 3 parts, cellular components (CC, e), biological process (BP, f) and molecular functions (MF, g)] and KEGG (h) pathway analysis of AKR1Cs and their altered neighbor genes in HCC. PPI network of all AKR1C members [AKR1C1 (i), AKR1C2 (j), AKR1C3 (k) and AKR1C4 (l)] showed protein-protein pairwise interactions.
Differentially expressed genes in correlation with AKR1Cs in HCC. Volcano plot showing genes correlated with AKR1Cs through Pearson analysis. Heat maps showing the top 50 genes positively and negatively correlated with AKR1Cs in HCC [AKR1C1 (a), AKR1C2 (b), AKR1C3 (c) and AKR1C4 (d)]. Red (positive), blue (negative).

Significantly enriched GO terms and KEGG pathway analyses of AKR1Cs [AKR1C1 (a), AKR1C2 (b), AKR1C3 (c) and AKR1C4 (d)] in HCC (GSEA). LeadingEdgeNum was used to conduct enrichment analysis and the top 10 items of each analysis were screened by false discovery rate (FDR) was 0 and p value was 0.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

Additional file 7.xlsx
Additional file 9.xlsx
Additional file 10.xlsx
Additional file 2.tif
Additional file 1.tif
Additional file 4.xlsx
Additional file 6.xlsx
Additional file 8.docx
Supplementary Figure Legends.docx
Additional file 5.xlsx
Additional file 3.xlsx